GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Accounts Receivable

Peak Bio (Peak Bio) Accounts Receivable : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Peak Bio's accounts receivables for the quarter that ended in Jun. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Peak Bio's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-1.00.

Peak Bio Accounts Receivable Historical Data

The historical data trend for Peak Bio's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peak Bio Accounts Receivable Chart

Peak Bio Annual Data
Trend Dec21 Dec22
Accounts Receivable
- -

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Accounts Receivable Get a 7-Day Free Trial - - - - -

Peak Bio Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Peak Bio Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Peak Bio's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Peak Bio's accounts receivable are only considered to be worth 75% of book value:

Peak Bio's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.214+0.75 * 0+0.5 * 0-21.114
-0-0)/20.8622
=-1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Peak Bio Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Peak Bio's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Peak Bio (Peak Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Accounts Receivable
Comparable Companies
NBRVF BXRX AMPE ADTX DRMA SCPS RUBY INM GLMD RVLPQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Website
https://www.peak-bio.com
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019